Edition:
United States

Zeba Siddiqui

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Jul 08 2017

Lupin sets off down Indian pharma's long road to redemption

GOA, India In 28 years in India's pharmaceuticals sector, Rajiv Desai has never been busier.

Jun 21 2017

SEBI tightens rules for offshore derivatives

MUMBAI The Securities and Exchange Board of India (SEBI) on Wednesday tightened regulations on offshore derivatives by increasing fees and banning the sale of certain products, while at the same time easing registration rules for foreign portfolio investors.

Jun 19 2017

Indian investors ride out big-pharma slump with small-cap drugmakers

MUMBAI Investors in Indian pharmaceutical stock, hit by quality-related sanctions against drugmakers operating abroad and reduced pricing power in more profitable markets, have adopted a new mantra: patience and pickiness.

Jun 07 2017

Exclusive: India regulator wants medical devices added to price control list, document shows

NEW DELHI/MUMBAI India's drug-pricing regulator has asked the health ministry to add four more medical devices to a list of products eligible for price controls to reduce costs to patients, which if agreed could be another blow to the country's $5 billion-a-year medical-technology industry.

Jun 07 2017

Exclusive - India regulator wants medical devices added to price control list, document shows

NEW DELHI/MUMBAI India's drug-pricing regulator has asked the health ministry to add four more medical devices to a list of products eligible for price controls to reduce costs to patients, which if agreed could be another blow to the country's $5 billion-a-year medical-technology industry.

May 27 2017

Sun Pharma says 2018 sales may fall as U.S. market gets tougher

MUMBAI India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers.

May 25 2017

India's Cipla lowers bio drugs investment, sharpens focus on respiratory

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday.

May 25 2017

Modi's generics-only drugs plan worries health experts, Indian pharma sector

MUMBAI India's plan to bring in a law to ensure doctors prescribe medicines only by their generic names risks proliferating the sale of substandard drugs in a country where regulation is already lax, doctors and pharmaceutical executives say.

May 24 2017

Lupin warns of more pricing pressure as fourth-quarter profit halves

MUMBAI Indian drugmaker Lupin Ltd expects to launch over 30 products in the United States this year, but warned revenue growth would remain muted due to growing pricing pressure and competition in the world's largest healthcare market.

May 18 2017

India's drug pricing regulator clamps down on drug cocktails

MUMBAI India's drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary